Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.bcp.2006.12.013
DC FieldValue
dc.titleContribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment
dc.contributor.authorHuang, C.
dc.contributor.authorIto, K.
dc.contributor.authorZhang, H.
dc.contributor.authorIto, Y.
dc.contributor.authorIda, H.
dc.date.accessioned2011-09-27T05:44:26Z
dc.date.available2011-09-27T05:44:26Z
dc.date.issued2007
dc.identifier.citationHuang, C., Ito, K., Zhang, H., Ito, Y., Ida, H. (2007). Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. Biochemical Pharmacology 73 (7) : 990-1000. ScholarBank@NUS Repository. https://doi.org/10.1016/j.bcp.2006.12.013
dc.identifier.issn00062952
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/27073
dc.description.abstractVorinostat (suberoylanilide hydroxamic acid, SAHA) represents a new class of highly potent histone deacetylase (HDAC) inhibitors that cause growth arrest, differentiation, and apoptosis of many tumor types in vitro and in vivo. RUNX3, a gastric tumor suppressor, is epigenetically silenced in gastric cancer cells. This study investigates the role of RUNX3 in vorinostat-induced suppression of gastric cancer cell growth. RUNX3 was up-regulated by vorinostat in gastric cancer cell lines not expressing RUNX3. In terms of cell viability, the mean IC50 of vorinostat in RUNX3-negative cells was significantly lower than that seen in RUNX3-positive cells, indicating that the former are more sensitive to vorinostat in terms of growth arrest than are RUNX3-positive lines. The mechanism underlying this difference was found to be reactivation of RUNX3 expression by vorinostat and concomitant increase in acetylated histone H3 in the promoter region of RUNX3. Using three RUNX3-negative cell lines, we determined the contribution of RUNX3 reactivation to growth inhibition and induction of apoptosis following treatment of cells with vorinostat and found that up-regulated RUNX3 was significantly responsible for tumor suppressive activities. © 2007 Elsevier Inc. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.bcp.2006.12.013
dc.sourceScopus
dc.subjectChemotherapy
dc.subjectGastric cancer
dc.subjectRUNX3
dc.subjectVorinostat
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.contributor.departmentNATIONAL UNIVERSITY MEDICAL INSTITUTES
dc.description.doi10.1016/j.bcp.2006.12.013
dc.description.sourcetitleBiochemical Pharmacology
dc.description.volume73
dc.description.issue7
dc.description.page990-1000
dc.identifier.isiut000245401300009
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

22
checked on Apr 1, 2020

WEB OF SCIENCETM
Citations

23
checked on Mar 24, 2020

Page view(s)

192
checked on Apr 1, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.